Everyday Health on MSN
These 19 online pharmacies can make getting your prescription so much easier
Skip the pharmacy line. These 19 trusted online pharmacies make refilling and managing your prescriptions easier, faster, and more convenient.
GoodRx is downgraded to neutral as declining consumer trends and policy risks outweigh prior valuation appeal. GDRX's active customer base fell 17% y/y in Q3, which the company blamed on Rite Aid ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...
Shares of LifeMD (LFMD) and GoodRx (GDRX) traded higher in the premarket on Monday after the companies announced the availability of Novo Nordisk’s (NVO) Wegovy pill as part of their product offerings ...
GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...
Shares of GoodRx Holdings Inc. sank in after-hours trading Monday after the company, which offers tools that help consumers compare drug prices, exceeded expectations with its March-quarter results ...
In terms of analyst actions, BofA Securities lowered its price target on GoodRx to $3.00 from $3.40, citing the company’s new weight loss initiatives. Despite this, TD Cowen reduced its price target ...
Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation GoodRx (Nasdaq: GDRX), the leading platform for ...
GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the cheap penny stocks to invest in. On December 18, Morgan Stanley lowered the firm’s price target on GoodRx to $4 from $5 and kept an Equal Weight rating ...
Hosted on MSN
GoodRx price target lowered to $2.60 from $3 at BofA
BofA analyst Allen Lutz lowered the firm’s price target on GoodRx (GDRX) to $2.60 from $3 and keeps an Underperform rating on the shares. Heading into 2026, the firm maintains its positive view on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results